Thyroid Eye Disease (TED) Clinical Trials

amgen rare disease logo

Tepro Subcutaneous Trial – soon to be opened for recruiting.

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.

FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.

Research presented  at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.


viridian therapeutics


ACELYRIN is currently recruiting for a clinical study designed to evaluate lonigutamab in subjects with TED. Use this link to learn more.


immunovant solutions for thyroid eye disease

Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.

See “Understanding Thyroid Eye Disease” contributed by Immunovant.


Lassen Therapeutics is currently recruiting for 2 clinical trials evaluating a novel treatment for people with TED.

Phase 2 clinical trial exploring LASN01 as a potential treatment for people with active TED

Phase 1 clinical trial further exploring LASN01 in people with active TED or idiopathic pulmonary fibrosis (IPF)


sling therapeutics

Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.

TED Clinical Trials / Studies for thyroid eye disease

Click this poster to open print / PDF version.